135 related articles for article (PubMed ID: 9805656)
41. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
[TBL] [Abstract][Full Text] [Related]
42. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies.
Burlingham WJ; Jankowska-Gan E; DeVito-Haynes L; Fechner JH; Hogan KT; Claas FH; Mulder A; Wang X; Ferrone S
J Immunol; 1998 Dec; 161(12):6705-14. PubMed ID: 9862700
[TBL] [Abstract][Full Text] [Related]
43. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype.
Ou D; Mitchell LA; Décarie D; Tingle AJ; Nepom GT
Hum Immunol; 1998 Mar; 59(3):149-57. PubMed ID: 9548074
[TBL] [Abstract][Full Text] [Related]
44. MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.
Held G; Wadle A; Dauth N; Stewart-Jones G; Sturm C; Thiel M; Zwick C; Dieckmann D; Schuler G; Hoogenboom HR; Lévy F; Cerundolo V; Pfreundschuh M; Renner C
Eur J Immunol; 2007 Jul; 37(7):2008-17. PubMed ID: 17559180
[TBL] [Abstract][Full Text] [Related]
45. Different regions of the N-terminal domains of HLA-DR1 influence recognition of individual peptide-DR1 complexes.
Tuosto L; Karr RW; Fu XT; Olson RR; Cundari E; Piccolella E; Lechler R; Lombardi G
Hum Immunol; 1994 Aug; 40(4):312-22. PubMed ID: 7528190
[TBL] [Abstract][Full Text] [Related]
46. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
47. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
Murthy VL; Stern LJ
Structure; 1997 Oct; 5(10):1385-96. PubMed ID: 9351812
[TBL] [Abstract][Full Text] [Related]
48. Properties of HLA class II molecules divergently associated with Goodpasture's disease.
Phelps RG; Jones V; Turner AN; Rees AJ
Int Immunol; 2000 Aug; 12(8):1135-43. PubMed ID: 10917888
[TBL] [Abstract][Full Text] [Related]
49. HLA-DR peptide-induced alloreactive T cell lines reveal an HLA-DR sequence that can be both "dominant" and "cryptic": evidence for allele-specific processing.
de Koster HS; van Rood JJ; Termijtelen A
Eur J Immunol; 1992 Jun; 22(6):1531-9. PubMed ID: 1376262
[TBL] [Abstract][Full Text] [Related]
50. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
Ito K; Bian HJ; Molina M; Han J; Magram J; Saar E; Belunis C; Bolin DR; Arceo R; Campbell R; Falcioni F; Vidović D; Hammer J; Nagy ZA
J Exp Med; 1996 Jun; 183(6):2635-44. PubMed ID: 8676084
[TBL] [Abstract][Full Text] [Related]
51. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.
Pajot A; Michel ML; Fazilleau N; Pancré V; Auriault C; Ojcius DM; Lemonnier FA; Lone YC
Eur J Immunol; 2004 Nov; 34(11):3060-9. PubMed ID: 15468058
[TBL] [Abstract][Full Text] [Related]
52. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
53. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
54. Sharing of four DR-beta sequence motifs between HLA-DRB1*1601 and DRB1*1101 correlates with frequent degenerate T-cell recognition of HA306-320 peptide complexed to these two molecules.
Zeliszewski D; Dorval I; Golvano JJ; Prevost A; Borras-Cuesta F; Sterkers G
Scand J Immunol; 1996 Feb; 43(2):146-54. PubMed ID: 8633194
[TBL] [Abstract][Full Text] [Related]
55. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
56. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
57. A Comparative Analysis of the Peptide Repertoires of HLA-DR Molecules Differentially Associated With Rheumatoid Arthritis.
Scholz E; Mestre-Ferrer A; Daura X; García-Medel N; Carrascal M; James EA; Kwok WW; Canals F; Álvarez I
Arthritis Rheumatol; 2016 Oct; 68(10):2412-21. PubMed ID: 27158783
[TBL] [Abstract][Full Text] [Related]
58. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.
Alexander-Miller MA; Parker KC; Tsukui T; Pendleton CD; Coligan JE; Berzofsky JA
Int Immunol; 1996 May; 8(5):641-9. PubMed ID: 8671651
[TBL] [Abstract][Full Text] [Related]
59. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
[TBL] [Abstract][Full Text] [Related]
60. Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules.
Sette A; Vitiello A; Farness P; Furze J; Sidney J; Claverie JM; Grey HM; Chesnut R
J Immunol; 1991 Dec; 147(11):3893-900. PubMed ID: 1658152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
